02:30:15 EST Wed 28 Feb 2024
Enter Symbol
or Name
USA
CA



Ventripoint Diagnostics Ltd (2)
Symbol VPT
Shares Issued 156,823,905
Close 2023-11-23 C$ 0.135
Market Cap C$ 21,171,227
Recent Sedar Documents

Ventripoint Diagnostics to release Q3 results Nov. 29

2023-11-24 09:55 ET - News Release

Mr. Jonathan Robinson reports

VENTRIPOINT ANNOUNCES DATE AND TIMING FOR RELEASE OF Q3 2023 FINANCIAL RESULTS AND WEBINAR

Ventripoint Diagnostics Ltd. will release its third quarter financial results and management discussion and analysis for 2023 on Wednesday, Nov. 29, 2023, after close of market. Ventripoint will host a webinar/conference call at 11 a.m. EST on Friday, Dec. 1, 2023, to discuss its Q3 2023 financial results and to provide an update on sales and marketing activities. Details of the webinar/conference call are as follows.

Participant telephone numbers

Canada/United States toll-free number:  1-844-763-8274

Toronto toll number:  1-647-484-8814

Please dial in five to 10 minutes prior to the scheduled start time and simply ask to join the call.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI (magnetic resonance imaging). This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.